National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Jump to:
loading...
Preferred Name

Liposome-Encapsulated Doxorubicin Citrate
Synonyms

liposome-encapsulated doxorubicin citrate

Liposome-Encapsulated Doxorubicin Citrate

DOXORUBICIN CITRATE

Myocet
Definitions

A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.
ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61317
ALT_DEFINITION

A form of the anticancer drug doxorubicin citrate that is contained inside very tiny, fat-like particles. It is being studied in the treatment of breast cancer that has spread and in the treatment of other types of cancer. Doxorubicin citrate damages DNA and may kill cancer cells. Liposomal-encapsulated doxorubicin citrate may have fewer side effects and may work better than doxorubicin citrate.
CAS_Registry

111266-55-8
code

C61317
Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537
Contributing_Source

CTRP

FDA

GDC
DEFINITION

A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity. Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and RNA synthesis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Liposomal delivery of doxorubicin improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects while lowering the toxicity profile.
Display_Name

Liposome-Encapsulated Doxorubicin Citrate
FDA_UNII_Code

AJQ2ZNG2WL
FULL_SYN

liposome-encapsulated doxorubicin citrate

Liposome-Encapsulated Doxorubicin Citrate

DOXORUBICIN CITRATE

Myocet
Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C18434
Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909
label

Liposome-Encapsulated Doxorubicin Citrate
Legacy Concept Name

Liposome-Encapsulated_Doxorubicin_Citrate
Maps_To

Liposome-Encapsulated Doxorubicin Citrate
NCI_Drug_Dictionary_ID

481301
PDQ_Closed_Trial_Search_ID

481301
PDQ_Open_Trial_Search_ID

481301
Preferred_Name

Liposome-Encapsulated Doxorubicin Citrate
prefixIRI

Thesaurus:C61317
Semantic_Type

Pharmacologic Substance
UMLS_CUI

C1512062
subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C67502
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display